DBVT

#1507

DBV Technologies S.A.

20.99

-2.01%

版块:

基础:

利润货币:

日范围

20.99

年范围

3.82

26.19

日变化

-2.01%

每月变动

-14.64%

6个月变化

+130.91%

年变化

+426.07%

前一天收盘价

21.42

Open

20.99

Bid

Ask

Low

20.99

High

20.99

交易量

市场
股票
医疗保健
DBVT

Open full chart

Financials

Overview 声明 Statistics Dividends

Quarterly Annual

Value Q3, 24Q4, 24Q1, 25Q2, 25Q3, 25 TTM

Key stats

Total common shares outstanding 19.3 M136.95 M136.95 M136.97 M169.11 M —

Valuation ratios

Enterprise value —390.72 M921.03 M1.15 B1.62 B 4.08 B Price to earnings ratio —-2.64-1.8-3.82-9.62 -17.87 Price to sales ratio —72.253115.63228.43 469.27 Price to cash flow ratio —2.872.065.2712.39 22.59 Price to book ratio —10.940.942.447.47 21.8 Enterprise value to EBITDA ratio ————— —

Profitability ratios

Return on assets % 0.330.350.540.290.3 1.48 Return on equity % 0.560.849.430.490.63 11.38 Return on invested capital % 383.73304.32368.28562.8443.95 1 679.34 Gross margin % 100100-469.19-307.17-32.66 -709.02 Operating margin % 2 829.14 669.473 534.932 806.211 235.65 12.25 K EBITDA margin % ————— — Net margin % 2 839.744 503.913 596.152 858.361 195.53 12.15 K

Liquidity ratios

Quick ratio ————— — Current ratio 2.221.430.722.451.8 6.4 Inventory turnover ————— — Asset turnover 0.010.010.010.020.02 0.06

Solvency ratios

Debt to assets ratio ————— — Debt to equity ratio ————— — Long term debt to total assets ratio ————— — Long term debt to total equity ratio ————— —

Per share metrics

Operating cash flow per share 1.170.130.190.290.26 0.86 EBIT per share ——-0.3-0.4-0.3 — EBITDA per share ————— — Total debt per share ————— — Cash per share 2.410.330.130.870.56 1.89 Net current asset value per share 3.570.460.281.020.71 2.48 Tangible book value per share 2.810.280.030.730.42 1.46 Working capital per share 1.970.14-0.110.610.32 0.95 Book value per share 2.810.280.030.730.42 1.46

DBV Technologies S.A. - American Depositary Shares

DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration.